Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Cytokinetics Incorporated is a biotechnology business based in the US. Cytokinetics Incorporated shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics Incorporated employs 184 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$35.73|
|52-week range||$14.89 - $39.46|
|50-day moving average||$34.27|
|200-day moving average||$27.34|
|Wall St. target price||$50.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-6.29%|
|1 month (2021-09-22)||5.59%|
|3 months (2021-07-22)||18.70%|
|6 months (2021-04-22)||37.42%|
|1 year (2020-10-21)||127.58%|
|2 years (2019-10-21)||214.52%|
|3 years (2018-10-19)||392.15%|
|5 years (2016-10-21)||288.79%|
|Revenue TTM||$57.8 million|
|Gross profit TTM||$-41,123,000|
|Return on assets TTM||-19.87%|
|Return on equity TTM||-1219.69%|
|Market capitalisation||$3.1 billion|
TTM: trailing 12 months
There are currently 10.5 million Cytokinetics Incorporated shares held short by investors – that's known as Cytokinetics Incorporated's "short interest". This figure is 1.8% down from 10.7 million last month.
There are a few different ways that this level of interest in shorting Cytokinetics Incorporated shares can be evaluated.
Cytokinetics Incorporated's "short interest ratio" (SIR) is the quantity of Cytokinetics Incorporated shares currently shorted divided by the average quantity of Cytokinetics Incorporated shares traded daily (recently around 945088.65886589). Cytokinetics Incorporated's SIR currently stands at 11.11. In other words for every 100,000 Cytokinetics Incorporated shares traded daily on the market, roughly 11110 shares are currently held short.
However Cytokinetics Incorporated's short interest can also be evaluated against the total number of Cytokinetics Incorporated shares, or, against the total number of tradable Cytokinetics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytokinetics Incorporated's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Cytokinetics Incorporated shares in existence, roughly 130 shares are currently held short) or 0.1265% of the tradable shares (for every 100,000 tradable Cytokinetics Incorporated shares, roughly 127 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cytokinetics Incorporated.
Find out more about how you can short Cytokinetics Incorporated stock.
We're not expecting Cytokinetics Incorporated to pay a dividend over the next 12 months.
Cytokinetics Incorporated's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics Incorporated shares which in turn could have impacted Cytokinetics Incorporated's share price.
Over the last 12 months, Cytokinetics Incorporated's shares have ranged in value from as little as $14.8901 up to $39.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics Incorporated's is 1.3101. This would suggest that Cytokinetics Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.